281 related articles for article (PubMed ID: 37335663)
21. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
Giri S; Tronvik E; Linde M; Pedersen SA; Hagen K
Cephalalgia; 2023 Apr; 43(4):3331024231156922. PubMed ID: 36856015
[TBL] [Abstract][Full Text] [Related]
22. Reaching the Nadir of Medication Overuse in Chronic Migraine.
Onan D; Wells-Gatnik WD; Martelletti P
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36429413
[TBL] [Abstract][Full Text] [Related]
23. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
24. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.
Do TP; Al-Saoudi A; Ashina M
Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458
[TBL] [Abstract][Full Text] [Related]
25. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
Eur J Neurol; 2022 May; 29(5):1505-1513. PubMed ID: 35098620
[TBL] [Abstract][Full Text] [Related]
26. CGRP Targeting Therapy for Chronic Migraine-Evidence from Clinical Trials and Real-world Studies.
Wang YF; Wang SJ
Curr Pain Headache Rep; 2022 Jul; 26(7):543-554. PubMed ID: 35567661
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.
Pellesi L; Guerzoni S; Pini LA
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):534-547. PubMed ID: 28409893
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
Ashina M; Cohen JM; Galic M; Campos VR; Barash S; Ning X; Kessler Y; Janka L; Diener HC
J Headache Pain; 2021 Jul; 22(1):68. PubMed ID: 34246226
[TBL] [Abstract][Full Text] [Related]
29. [CGRP antibodies in migraine prophylaxis : The new standard in migraine treatment?].
Hamann T; Rimmele F; Jürgens TP
Schmerz; 2022 Feb; 36(1):59-72. PubMed ID: 35041064
[TBL] [Abstract][Full Text] [Related]
30. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
Varnado OJ; Hoyt M; Ye W; Nicholson R
Curr Med Res Opin; 2022 Aug; 38(8):1451-1457. PubMed ID: 35762152
[TBL] [Abstract][Full Text] [Related]
31. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
Driessen MT; Cohen JM; Thompson SF; Patterson-Lomba O; Seminerio MJ; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
J Headache Pain; 2022 May; 23(1):56. PubMed ID: 35578182
[TBL] [Abstract][Full Text] [Related]
32. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
[TBL] [Abstract][Full Text] [Related]
33. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
Iannone LF; Burgalassi A; Vigani G; Tabasso G; De Cesaris F; Chiarugi A; Geppetti P
Cephalalgia; 2023 Apr; 43(4):3331024231160519. PubMed ID: 36918752
[TBL] [Abstract][Full Text] [Related]
34. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
Foster SA; Hoyt M; Ye W; Mason O; Ford JH
Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study.
Okonkwo R; Tockhorn-Heidenreich A; Stroud C; Paget MA; Matharu MS; Tassorelli C
J Headache Pain; 2021 Sep; 22(1):113. PubMed ID: 34592919
[TBL] [Abstract][Full Text] [Related]
36. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.
Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D
Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795
[TBL] [Abstract][Full Text] [Related]
37. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
38. A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine.
Reuter U
Headache; 2018 May; 58 Suppl 1():48-59. PubMed ID: 29697156
[TBL] [Abstract][Full Text] [Related]
39. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
40. Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review.
Kaltseis K; Hamann T; Gaul C; Broessner G
Headache; 2022 Nov; 62(10):1264-1271. PubMed ID: 36437611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
